资讯
Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.
Kevin Chinn, vice president and head of the cell & gene therapy service line at Cencora, outlines why early planning, ...
Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...
Answer ALS, a large-scale research initiative headquartered in New Orleans and Washington, D.C., has announced the launch of ...
Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation ...
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...
Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...
Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...
Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...
Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favora ...
Nobody knew anything." Worse still, she added, they "really didn't want to hear about it." Many clinicians remain unaware of ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果